Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyIn its initial session, the federal autism advisory committee spotlighted ‘profound autism’, a term garnering increased attention for its impact on policy and service provision. This post delves into the committee's objectives, challenges faced, and the broader implications for health care systems and families.
Daniel ChoApr 29, 2026
Regulatory & PolicyRoundup, a weedkiller previously at the center of numerous cancer-related claims, faces renewed scrutiny as the Supreme Court takes up the wave of lawsuits. This legal examination holds broad significance for regulatory frameworks, manufacturer liability, and public health policy.
Daniel ChoApr 28, 2026
Healthcare InvestmentIn a strategic move set to bolster the development of tumor-infiltrating lymphocyte (TIL) therapies, Obsidian Therapeutics and Galera Therapeutics have merged, securing substantial financial backing. This merger is poised to accelerate clinical trials and development pipelines designed to improve cancer treatment options for melanoma patients worldwide.
Daniel ChoApr 20, 2026
Regulatory & PolicyThe Centers for Medicare & Medicaid Services (CMS) intends to require nationwide participation in its CJR model, signifying the federal agency's commitment to broadening value-based care (VBC) adoption. While experts acknowledge the move as a logical and strategic extension of existing payment reforms, the practical realities of hospitals adapting to mandatory bundles reveal persistent implementation hurdles that merit careful examination.
Daniel ChoApr 19, 2026
Regulatory & PolicyLilly’s new obesity pill, Foundayo, has come under increased scrutiny after the FDA requested additional data amid concerns of serious safety risks, particularly regarding cardiovascular and liver health. The regulatory agency’s demand highlights the ongoing challenges of balancing innovative obesity treatments with patient safety requirements.
Daniel ChoApr 15, 2026
Regulatory & PolicyTravere Therapeutics has achieved a significant milestone with the FDA approval of Filspari for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. This approval is particularly notable due to the drug’s prior Phase 3 trial results, which did not meet expectations relative to a competitor medication. The decision showcases evolving regulatory perspectives in addressing unmet medical needs.
Daniel ChoApr 14, 2026
Biopharmaceutical IndustryIn a groundbreaking clinical development, Revolution Medicines has reported unprecedented trial data indicating that its targeted daily pill for metastatic pancreatic cancer patients significantly extends survival compared to traditional chemotherapy. This advancement heralds a possible shift toward more effective oral therapies in a disease with historically poor prognoses.
Daniel ChoApr 13, 2026
Regulatory & PolicySince the FDA began publicly sharing its drug approval rejections last year, the biopharmaceutical industry has witnessed a shift towards greater openness. This transparency fosters accountability, prompting companies to provide more comprehensive disclosures about FDA decisions, thereby informing stakeholders and enhancing trust in the regulatory process.
Daniel ChoApr 13, 2026
Regulatory & PolicyThe proposed budget for 2027 includes substantial reductions in healthcare spending, which experts warn could jeopardize patient care and biomedical research. This article explores the broader implications of the proposal and reactions from leaders in healthcare policy.
Daniel ChoApr 13, 2026
Biotech InnovationWith no FDA-approved therapies directly targeting GPC3 in hepatocellular carcinoma, Oricell’s cell therapy project aims to fill a critical unmet need in liver cancer treatment. However, it faces competition from major pharma and biotech players. This article explores the potential impact of Oricell's funding and the challenges ahead.
Daniel ChoApr 11, 2026
Regulatory & PolicyAfter facing criticism over cumbersome prior authorization procedures, health insurers have committed to reforms that are already yielding noticeable reductions. This article explores the extent of these changes, what they mean for patient care, and ongoing efforts by organizations such as AHIP and the Blue Cross Blue Shield Association to further enhance efficiencies in the health system.
Daniel ChoApr 9, 2026
Regulatory & PolicyRecent data highlight that the highest and lowest health spending metros in the United States do not follow a predictable pattern. Experts suggest that this randomness points to systemic inefficiencies and irrationalities in U.S. health care spending. This article delves into the details of this phenomenon and its implications for health policy and cost control.
Daniel ChoApr 9, 2026